<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Neopterin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB02385</strong>&#160; (EXPT02326)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>experimental</td></tr><tr><th>Description</th><td><p>A pteridine derivative present in body fluids; elevated levels result from immune system activation, malignant disease, allograft rejection, and viral infections. (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB02385/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB02385/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB02385.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB02385.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB02385.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB02385.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB02385.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB02385">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>2009-64-5</td></tr><tr><th>Weight</th><td>Average: 253.2147<br>Monoisotopic: 253.081103865</td></tr><tr><th>Chemical Formula</th><td>C<sub>9</sub>H<sub>11</sub>N<sub>5</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>BMQYVXCPAOLZOK-INEUFUBQSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C9H11N5O4/c10-9-13-7-5(8(18)14-9)12-3(1-11-7)6(17)4(16)2-15/h1,4,6,15-17H,2H2,(H3,10,11,13,14,18)/t4-,6-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-amino-6-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydropteridin-4-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=NC2=NC=C(N=C2C(=O)N1)[C@@H](O)[C@H](O)CO</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Pteridines and Derivatives</td></tr><tr><th>Subclass</th><td>Pterins and Derivatives</td></tr><tr><th>Direct parent</th><td>Pterins and Derivatives</td></tr><tr><th>Alternative parents</th><td>Pyrimidones; Primary Aromatic Amines; Pyrazines; Secondary Alcohols; 1,2-Diols; Polyamines; Primary Alcohols</td></tr><tr><th>Substituents</th><td>pyrimidone; primary aromatic amine; pyrazine; pyrimidine; polyol; 1,2-diol; secondary alcohol; polyamine; primary alcohol; alcohol; primary amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pterins and derivatives. These are polycyclic aromatic compounds containing a pterin moeity, which consist of a pteridine ring bearing a ketone and an amine group to form 2-aminopteridin-4(3H)-one.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Pharmacodynamics</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Mechanism of action</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Hyperphenylalaninemia due to 6-pyruvoyltetrahydropterin synthase deficiency (ptps)</td><td>Disease</td></tr><tr><td>Pterine Biosynthesis</td><td>Metabolic</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00005?highlight%5Bcompounds%5D%5B%5D=DB02385&amp;highlight%5Bproteins%5D%5B%5D=DB02385">SMP00005</a></td></tr><tr><td>Hyperphenylalaniemia due to guanosine triphosphate cyclohydrolase deficiency</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00487?highlight%5Bcompounds%5D%5B%5D=DB02385&amp;highlight%5Bproteins%5D%5B%5D=DB02385">SMP00487</a></td></tr><tr><td>Sepiapterin reductase deficiency</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00491?highlight%5Bcompounds%5D%5B%5D=DB02385&amp;highlight%5Bproteins%5D%5B%5D=DB02385">SMP00491</a></td></tr><tr><td>Hyperphenylalaninemia due to dhpr-deficiency</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00489?highlight%5Bcompounds%5D%5B%5D=DB02385&amp;highlight%5Bproteins%5D%5B%5D=DB02385">SMP00489</a></td></tr><tr><td>Dopa-responsive dystonia</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00486?highlight%5Bcompounds%5D%5B%5D=DB02385&amp;highlight%5Bproteins%5D%5B%5D=DB02385">SMP00486</a></td></tr><tr><td>Segawa syndrome</td><td>Disease</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00490?highlight%5Bcompounds%5D%5B%5D=DB02385&amp;highlight%5Bproteins%5D%5B%5D=DB02385">SMP00490</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9673</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.78</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7695</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5466</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9729</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9949</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9417</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8613</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6416</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.84</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9052</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9236</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9209</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9763</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.736
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9233
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9706
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1247 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9893
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9128
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>